Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
January 24 2023 - 9:00AM
Business Wire
Average weight loss of 3.7 pounds and an
average BMI reduction of 0.6 after 10 weeks in initial patients
Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the
“Company”), a medical technology company focused on developing and
commercializing non-invasive wearable sensors and supporting
personalized lifestyle and weight reduction programs, announces
initial results from patient studies of its metabolic health
program Miboko with the National Health Service (NHS) in the United
Kingdom.
The initial pilot program recruited 30 individuals that were
classified as obese according to their BMI. The first cohort of 10
patients have been enrolled in the program for over 12 weeks.
Results from this cohort indicate that these individuals achieved
an average weight loss of 3.7 pounds and an average BMI improvement
of 0.6 after 10 weeks, with 100% of participants achieving some
weight improvement. This level of average weight loss exceeds some
of the publicly reported results in studies of other weight loss
programs. As the Miboko program is optimized, average weight loss
is expected to increase. The program is designed to continue for at
least one year, with new patients being enrolled each month.
Feedback from participants shows that use of the body-worn
sensor led to greater engagement and an element of gamification
that is anticipated to lead to sustained use and encourage
incremental dietary and lifestyle changes through a combination of
personalized data and targeted education modules. Participants
expressed their willingness to continue with the program, reporting
that they do not see Miboko as a traditional diet plan, which the
Company expects will avoid diet fatigue and drop-off rates widely
associated with many of the current weight loss programs.
“These results are incredibly encouraging, as they validate the
approach that we developed some time ago that integrates the use of
a non-invasive glucose sensor with personalized, app-driven
coaching and analytics,” commented Faz Chowdhury, Ph.D., CEO of
Nemaura Medical. “We look forward to continuing the study with the
National Health Service and anticipate seeing increasingly robust
findings as we continue to follow these users and initiate new
users each month.”
The Miboko program is the first to integrate a daily-wear
non-invasive glucose sensor with a lifestyle app, which includes
recording of food and drink, educational content, and an analytics
platform. The wellness program provides each user a metabolic score
based on diet, exercise, and glucose response to food intake, which
is determined by the sensor. Users are given personalized
recommendations to help them lose weight, potentially avoid chronic
health issues , and enjoy a better quality of life.
As studies continue, lessons learned will be used to improve and
introduce new features into the program. The integration of
Nemaura’s daily-wear non-invasive glucose sensor is a unique
feature that is unavailable in any other plan, and the Company is
now evaluating options to provide the core part of the program and
glucose sensors as add-ons to existing diet and metabolic health
programs globally.
The Company expects the UK National Health Service will publish
detailed study results following further analysis.
About Miboko
Miboko integrates Nemaura’s non-invasive sensor with a diet and
wellbeing program to provide an indication of a person’s metabolic
health and wellbeing. The partnership with the UK’s NHS is through
medical centers that are partnered with the NHS’s National
Institute for Health and Care Research (NIHR) to gather information
that helps change and save lives. The Practice where the studies
are being undertaken are certified Research Ready by the Royal
College of General Practitioners and regularly undertakes
independent studies.
Miboko will be initially available without prescription and is
recommended for use by those wishing to lose weight and improve
their general health and wellbeing. The program will be relevant to
those with prediabetes as well as to people with obesity.
Significantly, Miboko will also be used by people who wish to
embark on a diet program, many of whom will have tried alternative
diet plans. The Company has plans to gather long-term outcome data
that could potentially support reimbursement.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing
and commercialising noninvasive wearable diagnostic devices. The
company is currently also commercialising sugarBEAT® and proBEAT™.
sugarBEAT® , a CE mark approved Class IIb medical device, as a
noninvasive and flexible continuous glucose monitor (CGM) providing
actionable insights derived from real time glucose measurements and
daily glucose trend data, which may help people with diabetes and
prediabetes to better manage, reverse, and prevent the onset of
diabetes. Nemaura has submitted a PMA (Premarket Approval
Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines
non-invasive glucose data processed using artificial intelligence
under a digital healthcare subscription service that has been
piloted in the U.S. as a general wellness product as part of its
BEAT® diabetes program.
The Company sits at the intersection of the global Type 2
diabetes market that is expected to reach nearly $59 billion by
2025, the $50+ billion pre-diabetic market, and the wearable
health-tech sector for weight loss and wellness applications that
is estimated to reach $60 billion by 2023.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, the launch of
proBEAT™ in the U.S., risks related to regulatory status and the
failure of future development and preliminary marketing efforts,
Nemaura’s ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Nemaura and its
partners’ ability to develop, market and sell proBEAT™, the
availability of substantial additional equity or debt capital to
support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to both
proBEAT™ digital health, and sugarBEAT®. There can be no assurance
that the company will be able to reach a part of or any of the
global market for CGM with its products/services. The U.S. Food and
Drug Administration (the “FDA”) reserves the right to re-evaluate
its decision that proBEAT™ qualifies as a general wellness product
should it become aware of any issues such as skin irritation or
other adverse events from the device, as well as any misuse
impacting patient safety, and any other reason as the FDA may see
fit at its discretion to determine the product does not fit the
definition of a general wellness product. There can be no assurance
that the KSA will approve the registration for
sugarBEAT® in Saudi Arabia.These and other risks and
uncertainties are identified and described in more detail in
Nemaura’s filings with the United States Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the most recently completed fiscal year, its
Quarterly Reports on Form 10- Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
For more information, please visit www.NemauraMedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230124005604/en/
CORE IR Jules Abraham +1 917-885-7378
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024